FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the "Announcement in Relation to the Approval for Clinical Trial regarding Investigational New Drug of a Subsidiary" published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang
Chairman

Shanghai, the PRC
20 October 2021

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Stock code: 600196 Stock abbreviation: Fosun Pharma Announcement No.: Lin 2021 - 142

Bond code: 143020 Bond abbreviation: 17 Fosun 01

Bond code: 143422 Bond abbreviation: 18 Fosun 01

Bond code: 155067 Bond abbreviation: 18 Fosun 02

Bond code: 155068 Bond abbreviation: 18 Fosun 03

Bond code: 175708 Bond abbreviation: 21 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Announcement in Relation to the Approval for Clinical Trial regarding Investigational New Drug of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and severally and jointly accept full responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

I. Overview

Fochon Pharmaceuticals, Ltd. ("**Fochon Pharmaceutical**"), a controlling subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") has recently received the approval from the National Medical Products Administration of consent to commence clinical trial of FCN-338 tablets (specifications: 10 mg, 25 mg and 100 mg) (the "**Investigational New Drug**") for relapsed or refractory B-cell lymphoma. Fochon Pharmaceutical intends to conduct Phase I clinical trial of the Investigational New Drug in the PRC (excluding Hong Kong and Macau SAR and Taiwan Region, hereinafter the same) in due course as and when the conditions permitted.

II. Research Progress of the Investigational New Drug

The Investigational New Drug is a small molecule inhibitor targeting Bcl-2 independently developed by the Group (i.e. the Company and its subsidiaries/units, hereinafter the same), which is proposed to be mainly used for the treatment for hematologic malignancies, relapsed or refractory B-cell lymphoma. As at the date of this announcement, the Investigational New Drug is at Phrase I clinical trial in the PRC for the treatment for hematologic malignancies.

As at the date of this announcement, drugs with the same target as the Investigational New Drug have been approved for launching in the PRC in December 2020. According to the data from IQVIA CHPA provided by IQVIA, a global leading provider of professional information and strategic consulting services for the pharmaceutical and health industry, IQVIA CHPA data represents the pharmaceutical sales market in hospitals with more than 100 beds in the PRC and the actual sales of different pharmaceutical products may differ to varying degrees from the IQVIA CHPA due to the layout of their respective sales channels, the sales of drugs with the same target as the Investigational New Drug amounted to approximately RMB4.68 million in the PRC from January to June 2021.

As at September 2021, the cumulative R&D investment of the Group in the Investigational New Drug for the treatment for hematologic malignancies, relapsed or refractory B-cell lymphoma was equivalent to approximately RMB63.14 million (unaudited) at this stage.

III. Risk Warning

As required by the relevant laws and regulations in the PRC, the Investigational New Drug is subject to a series of clinical studies for the relevant indications in the PRC and the approval from the national drug evaluation authority in the PRC before it can be launched. There are certain risks in the R&D of new drugs based on our experience. For example, clinical trials may be terminated due to issues such as safety and/or efficacy.

The R&D and marketing of new drugs is a long-term task involving various uncertainties. Investors should be aware of the investment risks.

Announcement is hereby given.

Board of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

20 October 2021